• Peiyi Yang, Yan Su, Wen Zhao, Chao Duan, Ying Li, Yuchen Zhou, Li Wang, Siyu Cai, Xuan Zhou, Xin Ni, and Xiaoli Ma.
• Medical Oncology Department, Pediatric Oncology Center，Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.
• Medicine (Baltimore). 2022 Dec 9; 101 (49): e31422e31422.

BackgroundSystematic pain management of children is insufficient in China, and there is no literature on pain in children with sarcoma.MethodsClinical data of 188 patients with newly diagnosed sarcoma admitted to the Medical Oncology Department of Beijing Children's Hospital was collected from October 2018 to December 2020. Children experiencing pain received analgesic treatment and regular assessment.ResultsThirty-seven patients (19.7%) suffered from pain. Six cases (16.2%) had mild pain, 17 (46.0%) moderate, and 14 (37.8%) severe. Daily lives of 31 patients were affected by pain. Twenty-six cases had bone invasion. The analgesic rate was 54.1% before admission and 89.2% after admission. Nine cases were treated with oral morphine regularly, and their pain was relieved before chemotherapy; the dose of morphine was 0.14 ± 0.034 mg/kgQ4H when the target was reached. No serious adverse reactions were observed. The period of morphine application after chemotherapy was 5 to 9 days, and there was no withdrawal reaction.ConclusionPain in children with newly diagnosed sarcoma was mainly moderate to severe, and the incidence of pain in sarcoma with bone invasion was higher, with greater intensity. Patients who received standardized pain assessment and regular analgesics reached pain relief quickly, and no serious adverse reactions were observed within the recommended dosage.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

26 keywords...

hide…